Pacific Biosciences of California, Inc. Stock News

MENLO PARK, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option (the “Option”) covering 100,000 shares of PacBio common stock, and restricted stock units (“RSUs”) covering 50,000 shares of...

Collaboration Aims to Harness HiFi Sequencing to Improve Diagnosis and Treatment of Subfertility and Recurrent Pregnancy Loss Collaboration Aims to Harness HiFi Sequencing to Improve Diagnosis and Treatment of Subfertility and Recurrent Pregnancy Loss

Highly Accurate Long-Read Sequencing Data from Revio will Support Germany's National Genome Initiative and Provide Data to the International Male Infertility Consortium Highly Accurate Long-Read Sequencing Data from Revio will Support Germany's National Genome Initiative and Provide Data to the International Male Infertility Consortium

MENLO PARK, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, at 1:05 p.m. Eastern Time.

PacBio's Q2 2024 revenue dropped 24% YoY, primarily due to a sharp decline in instrument sales. Gross margin plummeted to 16%, reflecting increased costs and pricing pressures in a challenging market. Rising SG&A expenses, including employee separation costs, are pressuring PacBio's already weakened financials.

A weak funding environment for life sciences tools has PacBio trading back below $2, as the company has come in well below prior revenue expectations and taken down mid-term targets. PacBio's Q2 was weaker than expected after a big miss-and-lower Q1, with instrument placements and revenue down sharply and consumables revenue impacted by weak utilization tied to customer budget limitations. PacB...

Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Todd Friedman - Senior Director of Investor Relations Christian Henry - President and Chief Executive Officer Susan Kim - Chief Financial Officer Conference Call Participants Dan Brennan - TD Cowen Jack Meehan - Nephron Research Madeline Mollman - Wolfe Research...

This joint effort will harness PacBio's state-of-the-art HiFi sequencing technology to offer profound insights into genetic diversity, disease mechanisms, and clinical diagnoses within Singapore's multi-ethnic population This joint effort will harness PacBio's state-of-the-art HiFi sequencing technology to offer profound insights into genetic diversity, disease mechanisms, and clinical diagnose...